Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a Phase III trial of Wainua (eplontersen) in transthyretin-mediated amy ...
If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results